The vote to authorize more shares was adjourned until December 1, 2008, and made in good faith compliance within the terms of the Iroquois financing agreement.
Will the company need additional shares to raise capital...absent a deal...undoubtedly...however issuance of the most recent MyoTech patent is a game changer in my humble opinion...as noted in the 10K.
The company is now free to do a Myo-Tech CSS "deal" with a potential licensee or a developmental partner, free of contingencies or conditional approval constraints by our former financial "friends"...enough said.